pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 25·1 min read
save

New Podcast 'Drug Story' Explores the Cultural Impact of Blockbuster Medications

Apr 25, 2026·read at STAT ↗Positive

The First Opinion team has launched a new podcast called “Drug Story,” hosted by journalist and entrepreneur Thomas Goetz. The series aims to uncover the hidden narratives behind widely used medicines.

Each episode examines how drugs such as Ambien, Ozempic, and EpiPens have shaped everyday life, influencing everything from personal habits to broader cultural trends. The conversations highlight both the intended benefits and the unexpected ways these treatments affect society.

Goetz discusses his perspective on the intersection of medicine and culture, and listeners are encouraged to subscribe via Apple Podcasts, Spotify, or their preferred platform. The podcast also offers a newsletter for updates on new episodes.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs”

read at STAT ↗
4,586 words · retrieved Apr 26
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Boundless Bio, Inc.
drugs
Obesity11Ambien6Edluar5Ozempic5Wegovy5IVERMECTIN4MDC-STM4QUIOFIC2Wegovy Pill2folic acid2ABRILADAAMJEVITAEPINEPHRINEEPIPEN E Z PENHUMIRASTERILE WATERYUSIMRYadalimumabinsulin
topics
Obesity11Immunology4Big Pharma2Infectious Disease2Endocrinology & MetabolismMajor DepressionOncologyType 2 DiabetesVaccineVaccines

related stories

  • 17h ago6 immunology targets to sustain a mammoth I&I marketBioSpace
  • Dec 22Fierce Biotech Fundraising Tracker '26: Sling reels in $123M; Circle gathers $92.5MFierce Biotech
  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • 5d agoNovo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzBioSpace
  • Sep 21Novo struggles to appease restive investors with consumer plans, blockbuster ambitionsFierce Biotech